Quantcast

Latest Tardive dyskinesia Stories

2011-04-05 08:00:00

SAN DIEGO, April 5, 2011 /PRNewswire/ --Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has completed the dosing and preliminary assessment of the initial cohort of Tardive Dyskinesia patients using its proprietary Vesicular Monoamine Transporter 2 inhibitor (VMAT2), NBI-98854. Based on this data, the Company is initiating the Investigational New Drug (IND) application process with the U.S. Food and Drug Administration (FDA). "We are very pleased with these preliminary...

2010-12-01 08:00:00

COMMACK, N.Y., Dec. 1, 2010 /PRNewswire/ -- The law office of Rudolph F.X. Migliore, P.C. announced today the firm is now accepting cases on behalf of people who used the prescription drug Reglan and later developed tardive dyskinesia, a neurological disorder that causes uncontrollable, repetitive movements of the body, such as grimacing, lip smacking, eye blinking or rapid leg and arm movements. The symptoms are rarely reversible and there is no known treatment. "Millions of Americans...

2010-10-18 07:00:00

SAN DIEGO, Oct. 18 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has successfully completed a second Phase I clinical trial of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The positive results of this Phase I study of repeated dosing in healthy volunteers allows the VMAT2 program to initiate Phase II studies. "Our VMAT2 inhibitor was well tolerated and again showed us the desired pharmacokinetic and safety...

2010-07-19 17:01:00

ATLANTA, July 19 /PRNewswire/ -- The law firm of Childers, Schlueter & Smith, LLC of Atlanta, Georgia has announced that a jury trial involving the drug Reglan/metoclopramide will be held during the week of July 26, 2010. The case is Susan Swicegood v. Pliva et. al. in the United States District Court, Northern District of Georgia, Atlanta Division. The lawsuit alleges that the drug makers and marketers of Reglan/metoclopramide failed to adequately warn physicians of the long-term...

2010-05-03 11:59:00

Reglan, metoclopramide never approved for use in infants HOUSTON, May 3 /PRNewswire-USNewswire/ -- Recently, researchers have observed a disturbing trend in neonatal units across the country: doctors prescribing Reglan -- also known by its generic name, metoclopramide -- to treat premature infants. This alarming development has raised serious concerns from many consumer safety advocates, particularly because the drug was never approved for use in infants. Reglan (metoclopramide) was...

2010-04-13 15:15:00

SAN DIEGO, April 13 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has received approval from Health Canada to commence its second Phase I clinical trial of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. "We are looking forward to starting our Phase I multiple repeated dose study of VMAT2 this month," said Christopher F. O'Brien, Chief Medical Officer of Neurocrine Biosciences. "Our VMAT2 inhibitor was well tolerated...

2010-04-13 07:11:00

GREENSBORO, N.C., April 13 /PRNewswire/ -- Merz Pharmaceuticals announces that results from several new studies examining Xeomin® (incobotulinumtoxinA), a botulinum neurotoxin type A (free from complexing proteins), also referred to as NT 201, will be presented today at the 62nd American Academy of Neurology (AAN) annual meeting in Toronto, Canada. Results of studies exploring the safety and efficacy of Xeomin® in the treatment of focal dystonias...

2010-03-09 14:33:00

Informs Public of Serious Risks Associated with Use of Reglan and Metoclopramide: Provides Solutions for Legal Recourse HOUSTON, March 9 /PRNewswire-USNewswire/ -- Blizzard, McCarthy & Nabers, one of the nation's leading pharmaceutical litigation firms is proud to announce the launch of ReglanJustice.com, an educational website aimed at informing consumers of the risks associated with the use of the drug Reglan, and its generic form, metoclopramide. As a resource for the millions of...

2010-03-05 12:33:00

Results achieved over 80 weeks of treatment consistent with statistically significant reduction in chorea demonstrated in pivotal study Lundbeck Inc. today announced the presentation of results from an open-label extension study of Xenazine® (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). Data from this study demonstrated that after an 80-week treatment period, subjects treated with Xenazine experienced a statistically significant...

2009-12-21 13:30:00

Clinical study seeks to validate dyskinesia clinical scales, lowering hurdle to industry investment in new treatments NEW YORK, Dec. 21 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research has awarded $1 million for a clinical study aiming to make a critical step toward the development of new treatments for dyskinesia, the excessive and uncontrollable movements that are a complication of long-term dopamine replacement therapy in patients with Parkinson's...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related